title: Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect.
abstract: There are sporadic reports of antipsychotic-induced visual hypersensitivity attack (VHA). VHA is characterized by hypersensitivity of perception mainly in the visual modality and sometimes accompanied by an oculogyric crisis. However, some researchers regard VHA as a schizophrenia symptom. To determine whether VHA is an adverse effect of antipsychotic agents, we examined the effect of dose reduction on VHA. This was an open-label 36-week study. We randomized 34 patients with VHA to a reduced-dose group and a fixed-dose group. Primary outcome measures were the frequency and duration of VHA, assessed with patients' self-reports, and the Clinical Global Impressions (CGI). Assessment also included the Drug-induced Extrapyramidal Symptoms Scale for extrapyramidal symptoms, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the CGI for other diagnoses. Data were collected from August 2000 to April 2005 at 4 psychiatric hospitals in Tokyo.VHA diminished in 16 patients (94.1%) in the reduced-dose group in the CGI score, the frequency (number of episodes per week), and the duration of the episodes (from 4.06 to 1.77, P < 0.001; from 2.59 to 0.82, P = 0.001; and from 1.92 to 0.66 hours, P = 0.007, respectively), but there were no changes in the fixed-dose group. There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA.
authors.affiliation: Department of Neuro-Psychiatry, School of Medicine, Keio University, Tokyo, Japan. mcn41320@biglobe.ne.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uchida
authors.forename: Takefumi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Ryoko
authors.initials: R
authors.lastname: Yamazawa
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tomita
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nemoto
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Kimura
authors.forename: Koichiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Imasaka
authors.forename: Haruo
authors.initials: H
authors.lastname: Kashima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D020795:Photophobia / Q000209:etiology*; D014796:Visual Perception / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents